Joseph Connors, MD: Bleomycin or Brentuximab Vedotin in Hodgkin Lymphoma?
1,629 views · Published 12 December 2017 · 6:24 · Indexed 21 October 2026
Channel: American Society of Hematology · 2017 · Nonprofits & Activism
Replacing bleomycin with brentuximab vedotin in standard ABVD therapy led to a "modest improvement" in outcomes for patients with Hodgkin lymphoma, without increased long-term toxicity. Dr. Connors shares results from the ECHELON 1 trial, which were presented as a plenary abstract at the 2017 ASH Annual Meeting.
More from this channel
-
1:52
Ron Reagan Accepts ASH Award - Stem Cell Research
-
4:25
Sen. Jim Talent's Work on Sickle Cell Disease Legislation
-
3:56
ASH and the Reagans Support Stem Cell Research
-
5:42
The American Society of Hematology Celebrates its 50th Anniversary
-
5:57
David Nathan Receives 2011 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
5:17
James George Receives 2012 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
2:21
Congress: Protect NIH funding
-
2:21
Act Now: Tell Congress to Stop Further Cuts to Research Funding